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ABSTRACT 
 Herein we report the synthesis of an RGD-ruthenium bipyridine [Ru(Bpy)2(BpyRGD)]2+ 
complex aimed at the detection of angiogenesis. Angiogenesis plays a critical role in many 
pathophysiological processes, such as tumor growth. The αv-integrins (αvβ3, αvβ5) are currently 
used as molecular targeting sites for anti-angiogenic therapies. The [Ru(Bpy)2(BpyRGD)]2+ 
complex is an organometallic luminescent probe, which enables noninvasive, in vitro imaging of 
αvβ3 expression. Peptides containing the arginine-glycine-aspartic acid (RGD) sequence have 
been shown to bind strongly to the αvβ3 integrin. The RuBpy probes are soluble in water, 
display long lifetimes, and are photochemically stable. These properties enable the Ru(tris-bpy) 
complexes to be useful in numerous applications in biophysical and cell biology. The 
[Ru(Bpy)2(BpyRGD)]2+ complex was synthesized by combining the succinimidyl ester on the 
RuBpy complex with the lysine of the c(RGDfK) peptide. The results of the one-photon 
fluorescence bioimaging showed selective binding of the cyclic RGD to αvβ3 integrin, which 
supports previous literature.  The high luminescence intensity, long lifetimes, and low cell 
toxicity levels of dye [Ru(Bpy)2(BpyRGD)]2+, illustrates the potential usage of this probe for 
future biological applications.   
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CHAPTER 1: BACKGROUND 
Cancer is a disease that may lead to death due to uncontrolled cell proliferation that 
creates masses inside the body known as tumors. Not all tumors are malignant, but given time 
these abnormal growths can metastasize, spread to other organs, and kill nearby healthy tissue. 
These characteristics differentiate cancers from benign tumors. When tumors are detected early 
the chances of survival are tremendously increased (Figure 1). However, most cancer patients 
are non-symptomatic, and by the time a diagnosis is reached the tumor may have become 
cancerous. 
 
Figure 1. Graph shows the correlation between survival rate and diagnosis at different cancer 
stages.9 
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In the early 1970s, it was suggested that tumor development and metastasis are dependent 
on angiogenesis, the process of forming new capillaries from pre-existing blood vessels.4 It has 
since been demonstrated that angiogenesis plays a critical role in many pathophysiological 
processes, for example: tumor growth, metastasis, rheumatoid arthritis, embryonic development, 
atherosclerosis, and post-ischemic vascularization of the myocardium.4 Therefore, detection of 
new pro-angiogenic, as well as anti-angiogenic molecules is vital for biomedical research.8 
Integrins are transmembrane receptor proteins that interconnect the extracellular matrix 
and the cytoskeleton. Integrins are typically made of 𝛼  and 𝛼𝛽  subunits.4 The 𝛼R v-integrins 
(𝛼Rv𝛽R3, 𝛼Rv𝛽R5) are currently used as molecular targeting sites for anti-angiogenic therapies.4 
Detection of 𝛼Rv𝛽R3 integrin that regulates angiogenesis is a major concern facing cancer 
researchers. A short peptide sequence arginine-glycine-aspartic acid (RGD) has been shown to 
selectively bind to endothelial tumor cells overexpressing 𝛼R v𝛽R 3 integrin.4 Attachment of a 
luminescent probe to an RGD containing peptide will enable noninvasive, in vitro, and perhaps, 
in vivo, imaging of 𝛼Rv𝛽R3 expression.  
One compound that has been explored as such a probe is ruthenium (II), the most stable 
oxidative state of ruthenium. Ruthenium is an uncommon transition metal. Similar to most 
metals, ruthenium is largely inert. Ruthenium complexes have unique characteristics which make 
them useful in numerous applications in biophysical chemistry, clinical chemistry, and DNA 
diagnostics. Advantages of these metal probes are their display of high chemical and 
photochemical stability, as well as its high luminescence, long lifetimes, and reasonable 
solubility in water.13  
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Ruthenium complexes are generally luminescent. Luminescence is the release of light 
(photons) by a substance.6 It occurs during the return of electrons to its ground state from the 
first singlet excited state.6 Fluorescence is the term used for emission of light for an excited 
singlet state while phosphorescence refers to emission of light from a triplet state, the ground 
state singlet state in both cases.6 In order for photons to be released the substance must first 
absorb a photon to reach an excited state.6 
 A fluorophore refers to the chromopric unit in a molecule that leads to light absorption 
and emission.6 Different fluorophores absorb photons at different wavelengths (λ). A molecule’s 
absorption is indicated by the wavelength of the molecule in a particular solvent. On average, the 
absorption of a photon takes roughly 10-15 s.11 Conversely, a molecule’s emission is affected by 
its excited state energy, solvent, and is indicated by the wavelength in which photons are emitted 
by the molecule. In order for emission to occur, the molecule needs to be excited at a specific 
wavelength, which is characterized by the maximum wavelength (λmax) of absorption.  
A Jablonski diagram (Figure 2) is a diagram that shows the electronic states of a 
molecule and the intermediate vibrational and rotational states of each electronic state.11 
Electrons aspire to get to the ground level, S0, where they are stable. When a substance is excited 
there are different energy levels to which the electrons can jump to, known as electronic 
transitions, S1, S2,…Sn.11 Rotational and vibrational levels are found between the electronic 
transitions levels. The excited electrons can lose their energy through vibrational relaxation (10-
12 - 10-10s), a non-radiative process in which an electron loses energy to the surroundings or 
through internal conversion between vibrational levels. Internal conversion is another type of 
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non-radiative process, where an excited molecule loses its energy from one electronic state to 
another. Internal conversion takes about 10-14 - 10-10s.11  
 
Figure 2. A Jablonski diagram.11 
 
Once a photon is absorbed by a molecule, an electron is promoted from the ground state 
to an excited state. Soon after excitation, electrons proceed down to their lowest closest 
electronic transition level by internal conversion through molecular rotations or vibrations.11 The 
desire for an electron to move down to its ground state gives it potential energy. The emission of 
a photon can occur as the electron drops back to its ground state. This is known as fluorescence 
if the transition is from an excited singlet state to the ground state singlet state.11  
When an electron undergoes internal conversion to the first electronic excited state, S1, it 
can behave in two different ways. The first possibility is for the electron to lose energy, returning 
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from S1 to the ground state (S0) via a radiative (fluorescence) and/or non-radiative mechanism. 
Second, the electron has the ability to transfer to a triplet excited state.11 The conversion of an 
electron from S1 to the triplet state and visa-versa is called intersystem crossing.11 During 
intersystem crossing the electron spin changes from antiparallel to parallel. In the triplet state, the 
electron is excited, but is slightly lower in energy compared to S1.6 From the triplet state, the 
electron can either return to S1 directly or fall to the ground state in a non-radiative or radiative 
fashion. This radiative energy loss is called Phosphorescence.6 Phosphorescence has a longer 
lifetime (10-3 to 102s) as compared to fluorescence (10-9 – 10-7s) since changing the multiplicity 
of states (spin) forbidden process.11  If the electron goes back to S1 and then falls to the ground 
state releasing photons, this is called delayed fluorescence.6 The lifetime of delayed fluorescence 
is also longer than fluorescence, again since changing the multiplicity of states (spin) forbidden 
process.6 Figure 3 shows a diagram of what happens to the electron during fluorescence, 
phosphorescence, and delayed fluorescence. Metal-ligand probes' have the ability to exhibit both 
phosphorescence and delayed fluorescence, due to its ability to experience metal to ligand charge 
transfer (MLCT) and, as a result, display long lifetimes.13 MLCT is an electronic transition that 
occurs between the metal to the ligand due to excitation.13 These long lifetimes allow the use of 
metal-ligand probes in time-gated detection.10 Additionally, metal-ligand probes can be used to 
suppress interfering autofluorescence, natural emission of light from biological samples; 
therefore, providing increased sensitivity.14                                       
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Figure 3. (A) Fluorescence, (B) phosphorescence, and (C) delayed fluorescence diagrams.1 
Ruthenium tris(bipyridine), Ru(tris-bpy), is a well-known polypyridine complex. 
Polypyridine complexes are compounds in which a polypyridine attaches to a metal ion, like 
ruthenium. The photophysical properties of ruthenium (II) polypyridine complexes are very well 
characterized.13 Ru(tris-bpy) complexes display decay times ranging from 100 ns to 10 μs.  
Ru(tris-bpy) absorbs ultraviolet and visible light. In an aqueous solution it absorbs at 452 nm 
with an extinction coefficient of 11,500 M−1cm−1.5 Solutions of the resulting excited complex 
have comparatively long lifetimes.5 The excited state relaxes to the ground state by emission of a 
photon at a wavelength of ca. 600 nm.5 
The specificity of a RGD-ruthenium bipyridine probe will enable the fluorescent labeling 
of sites where higher concentrations of the integrin are localized within cells, which could aid in 
the detection of small cancer tumors and, importantly, serve as markers of disease progression 
and the efficiency of anti-angiogenic therapy.2 
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Herein, is reported the synthesis of a long luminescent lifetime ruthenium 
complex, Ru(tris-bpy), and its subsequent conjugation to the cyclic peptide RGD, followed by 
linear characterization and cell bioimaging .   
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CHAPTER 2: EXPERIMENTAL SECTION 
2.1 Materials 
 The following were purchased from ACROS or Sigma Aldrich: 4,4'-dimethyl-2,2'-
bipyridyl, selenium(IV) oxide, 1,4-dioxane, ethyl acetate, sodium carbonate (Na2CO3), sodium 
metabisulfite anhydrous (Na2S2O5), dichloromethane (CH2Cl2), sodium sulfate (Na2SO4), 
ethanol (95%), silver nitrate (AgNO3), ultra-pure water, hydrochloric acid, acetic acid, sodium 
hydroxide pellets (NaOH), cis-bis(2,2′-bipyridine)dichlororuthenium(II) hydrate 
(Ru[(bpy)2]Cl2), ethanol (70%), hexafluorophosphoric acid (HPF6), 60 wt.% solution in water, 
ammonium hexafluorophosphate (NH4PF6), N-methylmorpholine (NMM), methyl sulfoxide-d6, 
for NMR, packaged in 1.00 mL ampoules, 99.9 atom % D, (CD3)2SO. N,N'-
dicyclohexylcarbodiimide, DCC was distilled. N-Hydroxysulfosuccinimide sodium salt, (NHS) 
was dried en vacuo. Acetonitrile, ACN, was distilled and dried over calcium (II) hydride. 2-
propanol (99.5+%) was dried. Cyclo (Arg-Ala-Asp-D- Phe-Lys), RGD, was purchased from 
Peptides International, Louisville, Kentucky, U.S.A.). 
 Cell Lines. U87MG cells and MCF7 cells were purchased from America Type Culture 
Collection, ATCC, Manassas, VA, U.S.A.  The incubation was done in Minimal Essential 
Medium (MEM) purchased from Life Technologies (Grand Island, New York, U.S.A.), 
supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA, 
U.S.A.) and 1% penicillin- streptomycin (Atlanta, GA, U.S.A.), and incubated at 37 ˚C in a 95% 
humidified atmosphere containing 5% CO2.  
2.2 Measurements 
 Varian 500 MHz nuclear magnetic resonance (NMR) and a Bruker Avance III 400 MHz 
NMR spectrometers were used to measure 1H and 13C NMR spectra. The different solvents used 
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were CDCl3, (CD3)2CO, (CD3)2SO, CD3CN.  The internal reference was tetramethysilane, 
TMS, at δ = 0.0 ppm. In order to predict and analyze the 1H and 13C NMR spectra, CS 
ChemDraw Ultra version 11.0 and Mestrec software were utilized. High-resolution mass 
spectrometry (HRMS) analysis was performed at the University of Florida’s Department of 
Chemistry.   
2.3 Synthesis 
 Details of the synthesis and characterization measurements of the intermediates and dye 1 
can be found in the following section, Results and Discussion.   
Synthesis of Intermediates 
 The intermediates (B, C, D, and E) have all been synthesized in the past.15 Slight 
modifications were done to previously published literature in order to produce to compound E.  
Synthesis of 4’-methyl-2,2’-bipyridine-4-carboxylaldehyde (B) 
4’-Methyl-2,2’-bipyridine (A) was used for the synthesis of B.  A mixture of A (10.54 g, 
57.21 mmol) and SeO2 (6.96 g, 62.73 mmol) in 1,4-dioxane (260 mL) was refluxed under 
nitrogen at slightly above 101 ˚C for 72 h. The reaction mixture was filtered hot and 
concentrated. The remaining solid was dissolved in ethyl acetate and then filtered. The filtrate 
was extracted with 1M Na2CO3 (4 x 100 mL) followed by 0.3M Na2S2O5 (6 x 100 mL). The 
product was determined to be in the aqueous phase. Additional Na2CO3 was added to the 
combined aqueous extracts until a pH of 10 was achieved and then extracted with CH2Cl2 (for 
every 350 mL of aqueous extract use 5 x 400 mL).15 The organic phase was dried with Na2SO4 
and purified by recrystallization using hexane to reveal a white powder (5.57 g, 49%): melting 
point 130-131 ˚C. 1 H NMR (500 MHz, (CD3)2SO) δ: 10.21 (s, 1H), 8.96 (d, J = 5 Hz, 1H), 8.80 
(d, J = 4 Hz, 1H), 8.60 (d, J = 5 Hz, 1H), 8.28 (d, J = 20 Hz, 1H), 7.87 (d, J = 10 Hz, 1H), 7.36 
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(d, J = 10 Hz, 1H) 2.47 (s, 3H). 13C NMR (500 MHz, (CD3)2SO) δ: 193.87, 157.39, 154.52, 
151.11, 149.68, 148.70, 143.05, 125.95, 122.31, 121.80, 119.88, 21.15.  
Synthesis of 4’-Methyl-2,2’-bipyridine-4-carboxylic acid (C) 
 A mixture of B (0.805 g, 4.06 mmol) with 95% ethanol (34.5 mL), AgNO3 (0.72 g, 4.24 
mmol), and H2O (7.5 mL) was degassed under nitrogen for 15 min. 1M NaOH was then added 
dropwise. The reaction mixture was left stirring under nitrogen overnight. The ethanol was 
evaporated off and then AgNO3 was filtered off and washed with 1.3 M NaOH (2 x 10 mL) and 
H2O (10 mL). The filtrate was extracted with CH2Cl2 (2 x 100 mL). The aqueous phase was 
collected and acidified to a pH 3.5 using 1:1 (v/v) 4N HCl:AcOH. The acidic solution was placed 
in a freezer at -10℃ overnight. The frozen solution was then left at room temperature, and the 
precipitate was filtered off and collected.15 Purified by recrystallization using ethyl acetate to 
reveal a white fluffy solid (0.444 g, 51%): melting point 279-280℃ . 1H NMR (400 MHz, 
(CD3)2SO) δ: 13.74 (broad s, 1H), 8.88 (d, J = 4 Hz, 1H), 8.83 (d, J = 4 Hz, 1H), 8.58 (d, J = 4 
Hz, 1H), 8.27 (d, J = 4 Hz, 1H), 7.87 (d, J = 8 Hz, 1H), 7.33 (d, J = 4 Hz, 1H), 2.44 (s, 3H). 13C 
NMR (400 MHz, (CD3)2SO) δ: 166.03, 156.44, 154.10, 150.16, 149.19, 148.06, 139.22, 125.37, 
122.63, 121.23, 119.42, 20.58. 
 Synthesis of Ruthenium(II)-bis(2,2’-bypiridine)-(4’-Methyl-2,2’-bipyridine-4-carboxylic 
acid)-bis(hexafluorophosphate) (D) 
 A mixture of Refluxed C (0.15 g, 0.70 mmol) and cis-dichlorobis(2,2-bipyridyl) 
ruthenium, Ru[(bpy)2]Cl2, (0.303g, 0.582 mmol)  in 70% ethanol (30 mL) heated under nitrogen 
at slightly above 100 ˚C overnight. The reaction mixture was cooled to room temperature and 
filtered. The ethanol was evaporated off. The rest of the reaction mixture was left at room 
temperature overnight. Solid was removed by filtration. HPF6 (60%) was added dropwise to the 
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filtrate to acidify to a pH 1 and form precipitate. A saturated solution of NH4PF6 until no more 
precipitation formed. Left at room temperature for 3 hours. Collected precipitate and washed 
with water (2 x 1 mL).15 The product is a dark red solid (0.417g, 95%). 1H NMR (500 MHz, 
CD3CN) δ: 8.90 (s, 1H), 8.55-8.50 (m, 5 H), 8.06- 8.09 (m, 4H), 7.92-7.91 (d, J = 5 Hz, 1H), 
7.78-7.71 (d, J = 5 Hz, 5H), 7.58-7.57 (d, J = 5 Hz, 1H), 7.43-7.38 (m, 4H), 7.29-7.28 (d, J = 5 
Hz, 1H), 3.25 (very broad s, 1H), 2.56 (s, 3H). 13C NMR (500 MHz, CD3CN) δ: 164.10, 155.78, 
152.85, 151.78, 150.76, 137.99, 127.66, 125.74, 124.33, 123.10, 20.26.  
Synthesis of Ruthenium(II)-bis(2,2’-bypiridine)-(4’-Methyl-2,2’-bipyridine-4-carboxamido-
methane)-bis(hexafluorophosphate) (E) 
 Compound D (0.05 g, 0.07966 mmol) and N-hydroxysuccinimide (NHS; 0.09168 g, 
0.07966 mmol) were dissolved in dry acetonitrile (ACN, 0.11 mL) under nitrogen. Then 
dicyclohexylcarbodiimide (DCC; 0.0214 g, 0.1036 mmol) was added. The reaction was left 
stirring under nitrogen overnight. The reaction mixture was filtered into a stirring solution of dry 
2-propanol (5mL). The mixture was left in the freezer at -10 ˚C overnight. The precipitate was 
then collected and washed with minimal amount of ultra-pure water.15 The product was a dark 
red solid (0.046g, 80%). 1H NMR (500 MHz, (CD3)2CO) δ: 9.03 (1H), 8.91 (1 H), 8.84 (4H), 
8.22 (4 H), 8.06 (4H), 7.87 (3H), 7.59 (4H), 7.44 (1H),  2.83 (4H), 2.63 (3H). IR ν 1732 – 1706 
(C=O), 1207 (C-O) cm-1. 
Synthesis of the RGD-ruthenium bipyridine [Ru(Bpy)2(BpyRGD)]2+ complex (1) 
 Compound E (12.7 mg, 0.0176 mmol) and RGD (10 mg, 0.016 mmol) were dissolved in 
(CD3)2SO (800 µL) in an NMR tube with a drop of N-methylmorpholine (NMM). The reaction 
was left stirring using a stir bar for 36 h. MALDI-TOF-MS [Ru(Bpy)2(BpyRGD)]2+ : m/z 
1226.03 [M - (CD3)2SO)]. Theoretical m/z 1,229.31 [M - (CD3)2SO)].  
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2.4 Linear Photophysical Properties 
 An Agilent (Model 8453) diode-array spectrometer was utilized for Ultraviolet–visible 
(UV-vis) absorption spectroscopy. Concentrations of 1×10-5 M of the precursor E and dye 1 
were prepared in ultra-pure water and acetonitrile at room temperature in 1 cm quartz cuvettes. 
Fluorescence emission measurements were obtained using a PTI International, Model MD-5020 
fluorometer. The quantum yields were calculated using a comparative method against 9,10-
diphenylanthracene,  DPA (QY = 0.95).12  
2.5 Cytotoxicity (MTS) Assay 
 To evaluate the cytotoxicity of dye, 1, 5 × 103 cells/well of U87MG cells in 96-well 
plates were incubated in 100 μL of MEM, supplemented with 10% Fetal Bovine Serum (FBS) 
and 1% penicillin-streptomycin for 48 h. Then the cells were incubated with several 
concentrations of dye 1 (0.5, 1.0, 1.5, 3.0, 5.0, 10.0, 15.0, 20.0 in µM), respectively, for an 
additional 22 h. Next, 20 μL of CellTiter 96 AQueous One Solution reagent was added into each 
well, followed by further incubation for 2 h at 37 ˚C. The relative viability of the MCF-7 and 
U87MG cells incubated with probe 1 to unaltered cells was determined by subtracting the 
absorbance of the cell-free medium blank (volume at 490 nm) by the absorbance of the MTS-
formazan on a microplate reader (Spectra Max M5, Molecular Devices, Sunnyvale, CA, U.S.A.) 
at 490 nm. Three individual experiments were prepared and averaged.3 
2.6 Cell Culture and Incubation  
 U87MG cells or MCF-7 cells were placed onto poly-D-lysine coated glass coverslips in 
24-well plates (60,000 cells per well), and the cells were incubated for 48 h before incubating 
with the dye 1. A 500µM stock solution of dye 1 was prepared in water. The solution was diluted 
to 5 μM with MEM, and then incubated for a period of an hour. Following incubation, the cells 
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were washed with PBS (x 3) and fixed using 3.7% formaldehyde solution for 10 min at 37 °C. 
Then freshly prepared NaBH4 (1 mg/mL, prepared by adding few drops of 6 N NaOH solution 
into PBS (pH = 7.2)) solution in PBS (pH = 8.0) was added to each well (0.5 mL/well) for 10 
min (x 2) (done to decrease autofluorescence). Afterwards the plates were washed with PBS (x 
2) and water. Lastly, the coverslips were mounted using Prolong Gold mounting media (Life 
Technologies) for microscopy.3 
2.7 Blocking Experiment 
 A blocking experiment was implemented in order to test the selectivity of the RGD-
containing ruthenium probe 1 to the αvβ3 integrin. U87MG cells were placed onto poly-D-lysine 
coated coverslips (12 mm) in 24-well plates (60,000 cells per well), and the cells were incubated 
for 48h. After, the cells were incubated with unlabeled cRGDfK (2 mg/mL of MEM) for 1 h. 
Then, 5 μM solution of dye 1 in MEM was added over the cells and incubated for a 1 h period. 
The cells were washed, treated, and mounted once incubation was completed.3 
2.8 One-Photon Fluorescence Imaging 
 Conventional one-photon fluorescence (1PF) images were obtained using an inverted 
microscope (Olympus IX-81) DSU microscope equipped with Hamamatsu EM-CCD C9100 
digital camera and mercury lamp (100 W). A custom designed filter cube (Ex 377/50, DM 409, 
Em 525/40) was used for the one-photon fluorescence microscopy imaging.3  
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CHAPTER 3: RESULTS & DISCUSSION 
3.1 Synthesis  
 Figure 4 shows the synthetic steps to prepare RGD-ruthenium bipyridine, 1.  The 
intermediates (B, C, D, and E) were reported previously.15 Slight modifications were done to 
previously published literature in order to produce compounds B, C, D, and E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Synthesis of the RGD-Ruthenium Bipyridine Probe [Ru(Bpy)2(BpyRGD)]2+. 
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Intermediate B was synthesized by the oxidation of a methyl group on 4’-methyl-2,2’-
bipyridine by the mild oxidant SeO2, which is being reduced. The reaction was monitored by thin 
layer chromatography, TLC. Probable side products are the oxidation to an aldehyde of both 
methyl groups on the 4’-methyl-2,2’-bipyridine reagent or a complete oxidation to a carboxylic 
acid of one or both methyl groups. These side products and excess reagents were removed 
through the steps discussed in the experimental section, such as filtration and various extractions. 
In order to remove the carboxylic acid the filtrate was extracted with Na2CO3. To protect the 
aldehyde an aldehyde bisulfate was formed by further extraction with Na2S2O3. The change of 
pH reformed the aldehyde. For the best results the aqueous phase was extracted with CH2Cl2 in 
sections. The best way to check if all of the aldehyde was extracted was by TLC and staining 
with 2,4-Dinitrophenylhydrazine, 2,4-DNPH stain. Ketones and aldehydes are detected by a 
yellow precipitate on the TLC plate. For purification hexane gave the best results for 
recrystallization. 1H and 13C NMR, as well as melting point were used to characterize the 
product. In the 1H NMR the aldehyde proton peak was found downfield at 10.21 ppm and the 
methyl protons were found upfield at 10.21 ppm. In the 13C NMR the carbonyl carbon peak was 
found downfield at 193.87 ppm and the methyl carbon was found upfield at 21.15 ppm. The 
melting point matched precious literature.7 
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Intermediate C was oxidized by AgNO3 in a redox reaction. The reaction was monitored 
using TLC and Bromocresol Green, BCG, stain, which detects different functional groups that 
have a pKa that is less than five. Carboxylic acids are stained green. The side products of this 
reaction are Ag2O and metallic silver, which are removed by filtration. To remove excess B, the 
mixture was extracted with CH2Cl2. In order to purify the compound, NaOH was used to turn the 
acid into a salt, making it water soluble. The acidic solution changed the salt back into a 
carboxylic acid inducing the precipitation. For purification ethyl acetate gave the best results for 
recrystallization. 1H and 13C NMR, as well as melting point were used to characterize the 
product. In the 1H NMR the carboxylic acid proton peak was found more downfield to the 
aldehydic proton peak from intermediate B at 13.74 ppm. This downfield shift was expected due 
to the increase in resonance and the electronegativity effect of the oxygen. The melting point 
matched precious literature.7 
Compound D was synthesized by using the reagent Ru[(bpy)2]Cl2, which is easily bound 
to each nitrogen on C under reflux. The reaction was monitored by TLC and the BCG stain, as 
well as UV-vis in ultra-pure water. The side products and excess reagents were removed by 
filtration. The pH was dropped dramatically in order to decrease the oxygen’s attractiveness to 
the Ru(II) metal. The product was precipitated out with the addition of saturated aqueous 
NH4PF6. Previous literature reviews had suggested washing with both water and ether; however, 
ether caused the product to change texture and became more of a paste.15 1H and 13C NMR, as 
well as UV-vis were used to characterize the product. The carboxylic acid proton peak in the 1H 
NMR was found to be an extremely broad peak from 2.75- 4.00 ppm.  The absorption λmax was at 
455 nm in ACN and 457 nm in ultra-pure water.  
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Compound E was synthesized by the activation of the acid by DCC, followed by the 
NHS coupling to the acid.  Succinimido esters are easily hydrolyzed by water; therefore, extra 
precautions were done for this reaction. Intermediate D was left under vacuum and heated 
(≥40˚C) for a few hours to insure dryness before use. The Schlenk tubes, stir bars, and solvents 
were also dried. The reaction was monitored by UV-vis in ACN. This reaction resulted in 
multiple side products such as dicyclohexylurea, confirmed with 1H NMR, and excess NHS, 
confirmed by TLC. In order to reduce the amount of side product once the reaction was 
complete, the reaction mixture was filtered two times. 1H NMR and IR were used to characterize 
the product. In the IR spectra the two ester peaks were found at 1732 – 1706 (C=O) and 1207 (C-
O) cm-1.  
Product 1 was synthesized by the conjugation of the succinimidyl functionality with the 
amine component of the c(RGDfK) peptide.  The cyclic RGD peptide was used to target αvβ3 
integrin. The αv- integrins are currently used as molecular targeting sites for anti-angiogenic 
therapies and RGD has been shown to mediate cell adhesion via the αvβ3 integrins. RGD has 
been shown to selectively bind to endothelial tumor cells over expressing αvβ3 integrins. The 
reaction was monitored by 1H NMR. Mass spectrometry was used to characterize the product.   
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3.2 Linear Photophysical Properties  
 The linear photophysical properties, UV-vis absorption, steady-state fluorescence, and 
fluorescence quantum yield (measure of emission efficiency) of E (Table 1) were carefully 
characterized in ultra-pure water and acetonitrile (Figure 5). DPA was used as the reference. In 
ultra-pure water the absorption λmax was equal to 457 nm and emission λmax was equal to 640 nm. 
The stoke shift was equal to 183 nm and the quantum yield (Φ) of E was found to be 0.05 ± 0.01. 
In acetonitrile the absorption λmax is equal to 455 nm and emission λmax is equal to 664 nm. The 
stoke shift was equal to 209 nm and the quantum yield of E was found to be 0.02 ± 5×10-3. The 
quantum yield was calculated by the equation shown in Figure 6.  
 
Table 1. Summary of normalized UV-visible absorbance, fluorescence emission spectra and 
stokes shift of precursor ([Ru(Bpy)2(BpyOH)]2+), E, and dye ([Ru(Bpy)2(BpyRGD)]2+), 1, in  
ultra-pure water and ACN. 
 
 
 
 
 
 
 
 
Compound Solvent Absorption λmax 
(nm) 
Emission λmax 
(nm) 
Stokes shift 
(nm) 
Φ 
E Ultra-pure water 457 640 183 0.05 ±  0.015 
E Acetonitrile 455 664 209 0.02 ± ×10-3 
1 Ultra-pure water 457 641 184 0.04 ± 0.01 
1 Acetonitrile  455 661 206 0.02 ± 5×10-3 
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Figure 5. Normalized UV-visible absorbance and fluorescence emission spectra of precursor 
([Ru(Bpy)2(BpyOH)]2+) in (A) ultra-pure water and (B) acetonitrile, respectively. 
 
   
 
 
 
 
 
  
Figure 6. Quantum Yield Equation 
 
The linear photophysical properties, UV-vis absorption, steady-state fluorescence, and 
fluorescence quantum yield, of 1 (Table 1) was carefully characterized in ultra-pure water and 
acetonitrile (Figure 7). DPA was used as the reference.12 In ultra-pure water the absorption λmax 
is equal to 457 nm and emission λmax is equal to 641 nm. The stoke shift was equal to 184 nm 
and the quantum yield of E was found to be 0.04 ± 0.01. In acetonitrile the absorption λmax is 
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equal to 455 nm and emission λmax is equal to 661. The stoke shift was equal to 184 nm and the 
quantum yield of E was found to be 0.02 ± 5×10-3.  
 
 
 
 
 
 
 
Figure 7.  Normalized UV-visible absorbance and fluorescence emission spectra of dye 
([Ru(Bpy)2(BpyRGD)]2+) in (A) ultra-pure water and (B) acetonitrile, respectively. 
 
 
Ultra-pure water was used as a solvent since the dye was dissolved in ultra-pure water for 
bioimaging. Acetonitrile was used as a solvent in order to have a reference. The absorption λmax 
for both E and 1 are equal in their respective solvents, since the cyclic RGD does not change the 
conjugation of E. The quantum yields were low in both solvents for both compounds; however, 
supporting data will show that dye 1 was still useful for bioimaging.   
3.3 Cell Viability Study 
Cytotoxicity of dye 1 was tested using an MTS assay, shown in Figure 8 at various 
concentrations were calculated. The concentrations utilized were 0.5, 1.0, 1.5, 3.0, 5.0, 10.0, 
15.0, 20.0 in µM. The MCF-7 cells showed excellent results of 100% viability after 24 h 
incubation time. These results also support the selectivity of the cyclic RGD to the αvβ3 integrin. 
The U87-MG cells results after 24 h of incubation were not as notable as MCF-7; however, the 
cell viability was high. From 0.5- 5.0 µM the cell viability was above 90%. From 10- 20 µM the 
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cell viability dropped to around 80%. These results indicate that the cytotoxicity of dye 1 is low, 
especially to the MCF-7 cell line.  
 
 
 
 
 
 
 
 
 
 
Figure 8.  Graph shows the percentage of viability among different µM concentrations of dye 
([Ru(Bpy)2(BpyRGD)]2+) in both U87MG and MCF-7 cells. 
 
3.4 One-Photon Fluorescence Bioimaging 
 The U87MG human gliobastoma cells and MCF-7 human breast cancer cells were used 
in order to test the selectivity of dye 1. One positive control was tested using the elevated 
integrin αvβ3 expressing U87-MG cells (Figure 9). Different concentrations and incubations 
times with dye 1 were tested; ranging from 1 µM to 10 µM and one to three hours of incubation 
time. The best results were seen at a concentration of 5 µM and an incubation time of one hour; 
there was high intensity fluorescence.   
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Figure 9. 1PF Images of U87MG Cells Labeled with dye 1 
 
Three negative control experiments were done. The blocking experiment was done in 
order to assure that dye 1 was only binding to the αvβ3 integrin by incubating the U87MG cells 
with the cyclic RGD peptide before the addition of dye 1. The fluorescence shown on the images 
(Figure 10) is autofluorescence from the U87MG cells.  
 
 
 
 
 
 
 
 
Figure 10. 1PF images of U87MG cells incubated with RGD before labeled with Ru-RGD 
probe. 
 
       (A) DIC                                         (B) 1                  (C) Overlay 
A B C 
                     (A) DIC                                            (B) RGD                                      (C) Overlay 
A B C 
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  The second U87MG negative control was incubating the U87MG cell line with the 
precursor E to see if there was any binding of any kind. Once again the fluorescence shown in 
Figure 11 is autofluorescence.  
 
 
 
 
 
 
 
 
 
Figure 11. 1PF images of U87MG Cells labeled with precursor E. 
 
The third negative control was using the MCF-7 cell line, which resulted in virtually no 
fluorescence (Figure 12). When comparing all three negative controls to the positive control 
there is a clear difference, the intensity of luminescence of the positive control U87MG cells are 
stronger compared to the negative controls. For the MCF-7 negative control the results are 
excellent due to little observable fluorescence after incubation.   
 
 
 
 
 
            (A) DIC                                        (B) E                              (C) Overlay 
B C A 
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Figure 12. 1PF images of negative control MCF7 cells. 
 
 
 
 
 
 
 
  
               (A) DIC                                             (B) Fluor                                           (C) Overlay 
A B  
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CHAPTER 4: CONCLUSION 
This study reports the successful synthesis and characterization of a ruthenium bipyridine 
complex and its successfully conjugation to the cyclic RGD peptide. The complex in solution 
had low fluorescence quantum yield. In contrast cell images showed fluorescence enhancement 
when the bioconjugate was introduced into the cells. The images indicate the 
([Ru(Bpy)2(BpyRGD)]2+) bioconjugate showed strong recognition of the high integrin αvβ3 
expressing U87MG cells and not the low integrin αvβ3 expressing MCF-7 cells. The cell 
viability tests indicated that the toxicity of complex is low, confirming a potential use of the 
bioconjugate for future studies in early tumor detection.  
Future work will entail the calculation of the probes lifetime, cell fluorescence lifetime 
imaging (FLIM), and the use of time-gated detection in order to reduce the effects of the 
interfering autofluoresence. Determining the binding site of the probe 1 on the cell will also be 
explored.  
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APPENDIX A: 
METHOD 2: SYNTHESIS OF [Ru(Bpy)2(BpyRGD)]2+ 
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The scheme above is an in situ reaction, which was another method that was attempted in 
order to synthesize [Ru(Bpy)2(BpyRGD)]2+. The reason this method was not carried out to 
completion was due to the unsuccessful purification of C, as well as the impracticality of 
isolating D.  The scheme below (part of the above scheme) was successfully synthesized.16   
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APPENDIX B: 
1H-NMR AND 13C-NMR OF 4'-METHYL-2,2'-BIPYRIDINE-4-
CARBALDEHYDE 
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APPENDIX C:  
1H-NMR AND 13C-NMR OF 4'-METHYL-2,2'-BIPYRIDINE-4-
CARBOXYLIC ACID  
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APPENDIX D: 
1H-NMR OF 2,5-DIOXOPYRROLIDIN-1-YL 4'-METHYL-2,2'-
BIPYRIDINE-4-CARBOXYLATE  
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APPENDIX E: 
 1H-NMR AND 13C-NMR OF RUTHENIUM (II)-BIS(2,2’-BYPIRIDINE)-(4’-
METHYL-2,2’-BIPYRIDINE-4-CARBOXYLIC ACID)-
BIS(HEXAFLUOROPHOSPHATE) 
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APPENDIX F: 
1H-NMR OF RUTHENIUM(II)-BIS(2,2’-BYPIRIDINE)-(4’-METHYL-2,2’-
BIPYRIDINE-4-CARBOXAMIDO-METHANE)-
BIS(HEXAFLUOROPHOSPHATE) 
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APPENDIX G: 
IR OF RUTHENIUM(II)-BIS(2,2’-BYPIRIDINE)-(4’-METHYL-2,2’-
BIPYRIDINE-4-CARBOXAMIDO-METHANE)-
BIS(HEXAFLUOROPHOSPHATE) 
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APPENDIX H: 
MASS SPECTROMETRY ([RU(BPY)2(BPYRGD)]2+) 
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